1. | ggordon100 | |
2. | rdjr2 | |
3. | robflutie | |
4. | 007Bondsman | |
5. | prncsstss0 |
1. | ggordon100 | |
2. | rdjr2 | |
3. | robflutie | |
4. | 007Bondsman | |
5. | prncsstss0 |
1. | rdjr2 07/05/2018 Celgene settled its litigations with Accord Healthcare relating to patents for REVLIMID |
2. | robflutie 10/23/2017 Here is what is expected {Link} |
3. | ggordon100 01/22/2018 Should add a lot |
4. | rdjr2 09/20/2018 Biotech Celgene Seen Rebounding 10% on Higher Sales |
5. | ggordon100 07/10/2018 Phase III IMpassion130 study met co-primary endpoint |
6. | robflutie 06/01/2018 Announces results from the OPTIMISMM study at ASCO |
7. | rdjr2 10/23/2017 They have a lot in the pipeline, so Friday was a blip |
8. | rdjr2 03/21/2018 JPMorgan resumes coverage as an overweight, $110PT |
9. | 007Bondsman 02/18/2018 OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis |
10. | rdjr2 01/23/2018 Surprised at the Neutral Rating Reiterate |